Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

References

• Wcrf.org [webpage on the Internet]Kidney cancer statistics [cited July 20, 2018]. Available from: https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/kidney-cancer-statisticsAccessed July 21, 2018
   Google Scholar
• LiPZnaorAHolcatovaIRegional geographic variations in kidney cancer incidence rates in European countriesEur Urol20156761134114125465966
   PubMed Web of Science ®Google Scholar
• Cancer.org [webpage on the Internet]. American Cancer SocietyKey Statistics about kidney cancer [cited July 20, 2018]. Available from: https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.htmlAccessed July 21, 2018
   Google Scholar
• JonaschEGaoJRathmellWKRenal cell carcinomaBMJ2014349g479725385470
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer Facts & FiguresAtlantaAmerican Cancer Society2017
   Google Scholar
• HarshmanLCChoueiriTKTargeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinomaCancer J201319431632323867513
   PubMed Web of Science ®Google Scholar
• RankinEBFuhKCCastelliniLDirect regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProc Natl Acad Sci U S A201411137133731337825187556
   PubMed Web of Science ®Google Scholar
• KoochekpourSJeffersMWangPHThe von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor- induced invasion and branching morphogenesis in renal carcinoma cellsMol Cell Biol19991995902591210454537
   PubMed Web of Science ®Google Scholar
• NakagawaMEmotoAHanadaTNasuNNomuraYTubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinomaBr J Urol19977956816879158500
   PubMedGoogle Scholar
• MotzerRJTannirNMMcDermottDFCheckMate 214 InvestigatorsNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaN Engl J Med2018378141277129029562145
   PubMed Web of Science ®Google Scholar
• LacySAMilesDRNguyenLTClinical Pharmacokinetics and Pharmacodynamics of CabozantinibClin Pharmacokinet201756547749127734291
   PubMed Web of Science ®Google Scholar
• ChoueiriTKHalabiSSanfordBLCabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialJ Clin Oncol201735659159728199818
   PubMed Web of Science ®Google Scholar
• ZhouLLiuXDSunMTargeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene201635212687269726364599
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTMETEOR investigatorsCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLancet Oncol201617791792727279544
   PubMed Web of Science ®Google Scholar
• ButiSBersanelliMIs Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?J Clin Oncol201735161858185928549228
   PubMed Web of Science ®Google Scholar
• Prisma-statement.org [webpage on the Internet]Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [cited July 20, 2018]. Available from: http://prisma-statement.org/PRISMAStatement/Accessed July 21, 2018
   Google Scholar
• ChoueiriTKHesselCHalabiSCabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression- free survival by independent review and overall survival updateEur J Cancer201894e125
   Web of Science ®Google Scholar
• GeorgeDJHesselCHalabiSCabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression- free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trialJ Clin Oncol201836Suppl 6582
   Web of Science ®Google Scholar
• FeldmanDRFeullyMMengJECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)J Clin Oncol20183615 Suppl
   Google Scholar
• ChenRCFeullyMMengJQuality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)J Clin Oncol201836Suppl abstr 4556
   Google Scholar
• SchmidtEListerJNeumannMCabozantinib Versus Standard- of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-AnalysisTarget Oncol20181320521629492762
   PubMed Web of Science ®Google Scholar
• WallisCJDKlaassenZBhindiBFirst-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisEur Urol Oncol2018743309321
   Google Scholar
• Clinicaltrials.govStudy of cabozantinib in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors [updated June 4, 2018; cited July 20, 2018]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03170960?term=NCT03170960&rank=1. NLM identifier: NCT03170960Accessed July 20, 2018
   Google Scholar
• ChoueiriTKApoloAPowlesTEscudierBArenORShahAA phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER)J Clin Oncol201836Suppl abstr TPS4598
   Google Scholar
• de VelascoGGonzálezBAlonsoTCABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC)J Clin Oncol201836Suppl abstr TPS4603
   Google Scholar
• Clinicaltrials.govCabozantinib S-malate, crizotinib, volitinib, or sunitinib malate in treating patients with locally advanced or metastatic kidney cancer [cited July 20, 2018]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02761057?term=NCT02761057&rank=1. NLM identifier: NCT02761057Accessed July 20, 2018
   Google Scholar
• ProcopioGRattaRFucGA phase 2 study of cabozantinib as first-line treatment in collecting ducts renal cell carcinoma: The BONSAI trialJ Clin Oncol2018366 SupplTPS709
   Web of Science ®Google Scholar
• Clinicaltrials.govCabozantinib Versus sunitinib for metastatic variant histology renal cell carcinoma [updated July 16, 2018; cited July 20, 2018]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03541902?term=NCT03541902&rank=1. NLM identifier: NCT03541902Accessed July 20, 2018
   Google Scholar
• SacksLVShamsuddinHHYasinskayaYIScientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012JAMA2014311437838424449316
   PubMed Web of Science ®Google Scholar
• GrignoloAPretoriusSPhase III Trial Failures: Costly, But PreventableAppl Clin Trial20162583642
   Google Scholar
• GrignoloAPretoriusSPhase III trial failures: costly, but preventableApplied Clinical Trials2016258
   Google Scholar